The FDA has placed a clinical hold on a LogicBio Therapeutics application to begin human testing of its experimental gene-editing therapy for a rare, inherited liver disorder.

LogicBio (NASDAQ: LOGC) disclosed the clinical hold for its gene-editing therapy, LB-001, after Monday’s market close. The Cambridge, MA-based biotech said that the hold concerns “certain clinical and nonclinical questions” for its submission. The company did not disclose any additional details about those questions.

Shares of LogicBio fell more than 26 percent to $7.70 apiece in after-hours trading.

LogicBio is developing its gene-editing therapy as a potential treatment for methylmalonic acidemia (MMA), a… Read more »